Vancomycin generic
vancomycin is an anti-bacterial drug owned by Xellia Pharms Aps. The active ingredient in vancomycin is vancomycin itself. This drug has been in the market since its first authorization on 26th August 2021. Out of the total 5 patents vancomycin holds, none have expired so far.
When will Vancomycin generic be available?
The generic version of Vancomycin is set to be potentially available after 6th November 2035. This is influenced by the expiry date of the patent US10849956 titled 'Glycopeptide compositions'.
Vancomycin uses
vancomycin is primarily used to treat bacterial infections. It works effectively by combating bacteria in the body. The active ingredient - vancomycin, contributes to its powerful anti-bacterial properties.
Vancomycin patent expiration
Vancomycin holds a total of 5 patents. The last of these patents, titled 'Glycopeptide compositions' (US10849956), is set to expire on 6th November 2035. This therefore influences when the Vancomycin generic will be available. Below are the details of the patent: